Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of two different regimens of
trastuzumab plus paclitaxel in treating women who have metastatic breast cancer that
overexpresses HER2.